Research library

D

grade

Not reported in abstract.

summary

B

grade

Children with combined pituitary hormone deficiency showed greater catch-up growth during rhGH therapy compared to those with isolated growth hormone deficiency, despite starting with more severe growth impairment.

Cumulative height SDS gains after 48 months: 3.10 ± 1.36 for CPHD vs. 1.92 ± 0.87 for IGHD, p < 0.001.

summary

B

grade

This study found that growth hormone therapy is associated with increased microstructural changes in the tibial tubercle in children, which may influence fracture risk. Adjusting physical activities during treatment may be advisable.

ADC was significantly higher at 8 months compared with baseline (1.61 × 10-3 vs 1.52 × 10-3 mm2/sec, p = 0.041).

summary

B

grade

A novel ACAN variant was found in a child with short stature, and growth hormone treatment led to initial catch-up growth, but further details on growth metrics were not provided.

Not reported in abstract.

summary

A

grade

Vitamin D supplementation appears to increase IGF-1 levels in children, and rhGH treatment can elevate vitamin D levels, but the clinical significance of these findings needs careful consideration.

WMD: 5.83 ng/mL increase in vitamin D levels after rhGH treatment, 95% CI: 3.72 to 7.94, p<0.00001.

summary

D

grade

Vitamin D supplementation may increase IGF-1 levels in children, particularly when combined with rhGH therapy, but the clinical implications of these findings require careful consideration.

WMD: 5.83 ng/mL increase in vitamin D levels after rhGH treatment, 95% CI: 3.72 to 7.94, p<0.00001.

summary

B

grade

A novel ACAN variant was identified in a child with short stature, and rhGH therapy led to initial growth improvements, but further details on long-term outcomes are lacking.

Not reported in abstract.

summary

B

grade

This case report shows a slight increase in height after rhGH treatment in a child with mosaic trisomy 14, but it does not provide evidence for treatment efficacy or safety.

Height increased by 1.9 cm after three months.

summary

A

grade

In adults with growth hormone deficiency, rhGH therapy was associated with decreased asprosin levels and improvements in body composition over 24 months.

Not reported in abstract.

summary

B

grade

Children with combined pituitary hormone deficiency showed greater catch-up growth during rhGH therapy compared to those with isolated growth hormone deficiency, despite starting with more severe growth impairment.

Cumulative height SDS gains after 48 months: CPHD 3.10 ± 1.36 vs IGHD 1.92 ± 0.87; p < 0.001.

summary

B

grade

Peak growth hormone levels do not appear to predict growth response in children with growth hormone deficiency, suggesting a broader clinical evaluation is necessary.

Group 1 had higher BMI (median 16.1 vs 15.0 kg/m², P < 0.001)

summary

A

grade

Lonapegsomatropin shows low immunogenicity in children with GHD, with transient antibody responses primarily occurring in the first year of treatment.

4.7% of treated children developed anti-lonapegsomatropin antibodies.

summary

B

grade

This case shows a significant growth response to rhGH therapy in a child with ZTTK syndrome, despite normal GH levels.

>50% increase in height velocity from baseline (4.3-7.2 cm/year).

summary

C

grade

This study highlights the connection between gut microbiota and growth impairment in children with persistent diarrhea, suggesting potential avenues for targeted interventions.

Not reported in abstract.

summary

B

grade

This case demonstrates a significant growth response to rhGH therapy in a child with ZTTK syndrome, despite normal GH levels, highlighting the need for supervised trials in similar cases.

>50% increase in height velocity from baseline (4.3-7.2 cm/year).

summary

B

grade

This case report suggests that recombinant human growth hormone may support catch-up growth in a patient with Takenouchi-Kosaki syndrome, but further research is needed to confirm its efficacy and safety.

Not reported in abstract.

summary

B

grade

Easypod may provide greater height gains and cost savings compared to nonconnected devices for pediatric patients with growth hormone deficiency, but results are based on a model and may not reflect all real-world factors.

Projected final height at bone maturation was 163.04 cm with Easypod versus 159.21 cm with nonconnected devices, an incremental gain of 3.83 cm.

summary

B

grade

In two patients with novel IGF1R variants, rhGH therapy resulted in a modest height gain in one case, while the other showed no growth response. This highlights the variability in treatment outcomes.

+0.3 SDS per year height gain in Case 1 after 2 years of rhGH therapy.

summary

B

grade

This study highlights the importance of ongoing surveillance for safety signals associated with recombinant human growth hormone in pediatric patients.

167 positive signals identified across 19 System Organ Classes.

summary

D

grade

This study identified 167 positive safety signals associated with rhGH in pediatric patients, highlighting the importance of ongoing surveillance for adverse events.

167 positive signals identified across 19 System Organ Classes.

summary

D

grade

Not reported in abstract.

summary

B

grade

Management of short stature in youth following GH testing varies widely, even within a single institution, reflecting differing clinical practices.

53% of participants had peak GH ≥10 ng/ml.

summary

C

grade

This study presents a validated potency assay for rhGH that may improve the accuracy of potency assessments in biopharmaceutical manufacturing.

GCV 8.4-18.3% for intermediate precision.

summary

A

grade

Somatrogon-treated patients showed similar height outcomes compared to those treated with daily somatropin over three years, suggesting comparable efficacy in real-world settings.

Y1: 10.03 cm/year vs 9.57 cm/year for somatrogon vs somatropin, n=155 each cohort.

summary

B

grade

LAGH preparations show comparable efficacy to daily somatropin, but careful patient selection and monitoring are crucial.

Data available for up to 7 years of LAGH treatment in over 8,000 individuals.

summary